IGF-1 DES (1-3) Dosing Protocol: Local IGF-1 vs. IGF-1 LR3 Guide
Also known as: DES(1-3)IGF-1, Truncated 67-AA Local IGF-1 Analog, IGF-1 DES vs. IGF-1 LR3
Studied in published research — not a medical recommendation. Primary protocol (Site-Specific Local / Peritendinous Research Protocol): 20–50 mcg total (split 10–25 mcg bilaterally into target tissue), Training or rehabilitation days only (3–5x/week immediately pre- or post-session).
Training or rehabilitation days only (3–5x/week immediately pre- or post-session)
Research-reported range (no primary dosing study). Keep fast-acting carbohydrates on hand for 45 minutes post-administration; much shorter hypoglycemia monitoring window than IGF-1 LR3
Subcutaneous peritendinous or shallow intramuscular
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 250 doses in the vial at the low end (100 doses at the high end).
Save IGF-1 DES (1-3) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Peptide?
A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.
Bottom Line Up Front
IGF-1 DES (DES(1-3)IGF-1) is a truncated 67-AA variant lacking the N-terminal Gly-Pro-Glu tripeptide. It has <1% affinity for inhibitory IGF-Binding Proteins (IGFBPs), giving it ~10x local receptor potency and a short 20–30 minute half-life for targeted site-specific recovery vs 20–30 hr systemic IGF-1 LR3.
Site-specific IGF-1R activation and satellite cell hyperplasia with rapid systemic clearance
24-hour systemic elevation (where IGF-1 LR3 or GH secretagogues act longer)
None
3 (0 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. IGF-1 DES (1-3) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
Endogenous 70-amino-acid IGF-1 circulates 98%+ bound to IGF-Binding Proteins (especially IGFBP-3), which blunt its immediate bioactivity. In human brain, colostrum, and mechanically stressed muscle tissue, proteases cleave off the N-terminal tripeptide (Gly-Pro-Glu) to generate DES(1-3)IGF-1 (67 amino acids). Because Glutamate at position 3 is required for IGFBP docking, IGF-1 DES bypasses IGFBPs entirely and binds with 5–10x higher functional potency to local Type 1 IGF receptors (IGF-1R)—especially in lactic-acidified tissue—before clearing the bloodstream within 20–30 minutes.
Mechanisms of Action
- Lacks N-terminal Gly-Pro-Glu (residues 1–3), eliminating >99% of inhibitory binding to IGFBP-1 through IGFBP-6
- Activates PI3K/Akt/mTOR and MAPK/ERK cascades at local Type 1 IGF receptors with ~10x higher functional bioactivity than native IGF-1
- Maintains high receptor affinity in acidic microenvironments (such as injured tendons or lactate-accumulated muscle)
- Rapid ~20–30 minute plasma half-life minimizes prolonged visceral organ exposure compared to 20–30 hour IGF-1 LR3
Common Ratios, Vial Formats & Dosing Breakdown
Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.
IGF-1 DES (Local 20–30 min Half-Life) vs. IGF-1 LR3 (Systemic 20–30 hr Half-Life)
1 mg lyophilized vial (reconstituted with 1–2 mL BAC water or 0.6% Acetic Acid)
IGF-1 DES: 20–50 mcg bilateral local pre/post-training · IGF-1 LR3: 20–40 mcg systemic once daily
Why this ratio: Choose IGF-1 DES for site-specific repair and minimal systemic hypoglycemia window; choose IGF-1 LR3 only for full-body 24-hour signaling with strict 4-week cycling.
Research Protocols
Summaries of published research. For educational purposes only.
| Protocol Name | Source | Dose | Frequency | Duration | Route | Evidence | Link | Save |
|---|---|---|---|---|---|---|---|---|
| Site-Specific Local / Peritendinous Research Protocol | reported protocol | 20–50 mcg total (split 10–25 mcg bilaterally into target tissue) | Training or rehabilitation days only (3–5x/week immediately pre- or post-session) | 4 weeks on, followed by 4 weeks off to prevent IGF-1R downregulation | Subcutaneous peritendinous or shallow intramuscular | animal | — |
GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (IGF-1 DES (1-3))
Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.
Serum IGF-1 (LC/MS) + Z-Score
Day 0 + Wk 6–8Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.
Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).
Fasting Insulin & HOMA-IR
Day 0 + Wk 6–8Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.
Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.
HbA1c & Fasting Plasma Glucose
Day 0 + Wk 6–8Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.
Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.
hs-CRP, Prolactin & CMP
Day 0 + Wk 6–8Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.
Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Contraindicated in anyone with active malignancy, history of cancer, or diabetic retinopathy (potent mitogenic growth factor)
- •Can cause acute transient hypoglycemia within 15–45 minutes if administered fasted via insulin-receptor cross-talk
- •Prohibited at all times by WADA under Section S2.2 (IGF-1 and its analogues)
- •Limit cycles to 4 weeks maximum to avoid local IGF-1 receptor desensitization
Where to get IGF-1 DES (1-3), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More hormonal peptides
CJC-1295 (No DAC / Mod GRF 1-29)
CJC-1295 is a synthetic analog of growth hormone-releasing h...
Ipamorelin
Ipamorelin is a growth hormone secretagogue that selectively...
GHRP-2 (Pralmorelin)
GHRP-2 is a synthetic growth hormone-releasing peptide that ...
GHRP-6
GHRP-6 is a first-generation growth hormone-releasing peptid...
Hexarelin
Hexarelin is a synthetic growth hormone-releasing peptide (G...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.